OneOme

Lack of standardized, high-resolution data transfer from laboratories into EHR systems may impact patient safety, efficiency and PGx utility. Read about our lessons learned and new high-resolution workflow. “Standardizing Return of Pharmacogenomic Results into EHR Systems” – Presented at ClinPGX 2024 by Annmarie Hawe is now available for download at https://lnkd.in/gcgz8d7q

Specific HLA variants put patients at risk of SJS/TEN with meds including carbamazepine, oxcarbazepine, phenytoin, and allopurinol. We found a higher rate of clinically actionable variants than previously reported. “Frequency of HLA Polymorphisms in a Large Population Related to Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) Development Risk” – Presented at ClinPGX 2024 by Victor Tam, PharmD is now available for download https://lnkd.in/gcgz8d7q

Utilizing PGx to guide drug selection and dosing for cancer patients with depression may reduce trial/error, time to effective therapy, limit burden, improve QOL. “The role of personalized therapy in cancer associated depression among 10,673 patients” – Presented at ASCO 2024 by Ghada Elnashar, PharmD, MS is now available for download https://lnkd.in/gcgz8d7q

Are you testing patients for toxicity-associated biomarkers before starting chemotherapy? These biomarkers may be more common than you think. “Frequency of certain germline polymorphisms among ethnicities and adverse drug reaction risk associated with colorectal cancer therapies” – Presented at ASCO 2024 by Cathryn Jennissen, PharmD, BCOP is now available for download at https://lnkd.in/gcgz8d7q

OneOme welcomes and applauds the statement from the American Heart Association (AHA) that supports the value of CYP2C19 testing for antiplatelet therapy (oral P2Y12 inhibitors). The AHA also highlights the importance of proper implementation of PGx testing for clinician and health system adoption. https://lnkd.in/g2Yff83z

Let's connect at ClinPGx! Brett Miller, Victor Tam, PharmD, Annmarie Hawe and Jason Walker will be on site to learn and share our scientific posters. We'd love to hear about your PGx program and what you've learned along the way.

OneOme posters will be up this afternoon. Ghada and Cathryn would love to walk you through them! #ASCO2024

Ghada Elnashar, PharmD, MS spoke with clinicians and the driven team at Advocates for Universal DPD/DPYD Testing. Topics of the day: misperceptrions about variant frequency across different populations, PGx test turnaround time, and how to make testing as easy/automatic as possible for oncologists. Great problem solving at #asco2024

OneOme’s Ghada Elnashar, PharmD, MS will be at the Advocates for Universal DPD/DPYD Testing at 11:45 today discussing the importance of DPYD testing for patient safety. Booth #11027. See you there!

OneOme clinicians are presenting new scientific posters at ASCO! Ghada Elnashar, PharmD, MS will be presenting: The role of personalized therapy in cancer associated depression among 10,673 patients. Cathryn Jennissen, PharmD, BCOP will be presenting: Frequency of certain germline polymorphisms among ethnicities and adverse drug reaction risk associated with colorectal cancer therapies.